Home' Australian Pharmacist : Australian Pharmacist August 2012 Contents 608 Australian Pharmacist August 2012 I ©Pharmaceutical Society of Australia Ltd.
Managing con icts of interest
The National Health and Medical Research
Council (NHMRC) has strengthened
its policies to ensure clinical advice
is not tainted by undeclared or
on experts, who
and interests to the table. The new policy
ensures that transparency, a balance of
perspectives and guidance on disclosing
and managing interests lead to the best
possible advice for health practitioners
and policy makers.'
The new policy was developed through
two rounds of public consultation and
has been provided to key organisations
involved in guideline development.
Starting 1 August, Guideline
Development Committee members are
required to declare their interests. Any
con icts of interest will be managed
using a range of options that can be
tailored to meet the circumstances.
The new policy encourages open and
direct discussions about interests for
advisory committees, in a transparent
and responsible way. These discussions
are a constant theme during committee
meetings, not just a process done at the
'This policy re ects international
best practice and will maintain
Australia's position at the forefront
of evidence-based health advice. It
re ects a principle-based approach
because, ultimately, managing interests
appropriately requires both judgement
and commitment to transparency,'
Professor Anderson said.
This policy extends far beyond NHMRC's
advisory committees. All guideline
developers seeking approval under the
National Health and Medical Research
Council Act, 1992 will need to demonstrate
their implementation of the new policy.
'We want to see all Australian guideline
developers and research institutions
adopting the same commitment to
identifying and managing con icts of
interest. Anyone using NHMRC advice,
or NHMRC approved advice, can have
con dence it does re ect the evidence
and can be relied on.'
The new policy on Guideline
Development and Con icts of Interest is
available on the NHMRC website at: www.
Cold and u advice
NPS has developed some quick questions
for people su ering from a cold or u
to help them seek advice from their
health professional on how to treat
NPS clinical adviser Dr Philippa Binns
says that with colds and u abundant at
this time of year, and with reported u
spikes in some parts of the country, it's
important people equip themselves with
the information they need to manage
the symptoms of their illness and help
themselves feel better.
'She said that the questions should
help people get the information they
need from their doctor, pharmacist
or other health professional to treat
symptoms e ectively.
'In spite of the fact that colds and u are
viral infections and do not respond to
antibiotics many people still expect to
be prescribed them. It would be nice if
there was a magic pill that would make
our illness disappear but unfortunately if
you have a virus, then antibiotics are not
Practicing good hygiene is an important
step to help stop the spread and prevent
colds and u in the rst place.
The NPS top ve questions to ask
about cough, cold or u
1. How long will I take to get better, and
when can I return to work/school?
2. How can I prevent my problem from
spreading to others?
3. How can I relieve my symptoms?
4. Could any over-the-counter medicines
help my condition?
5. When should I seek further help from a
Protein and peptide
According an new report on protein
and peptide based therapeutics
released by healthcare experts
GBI Research there are currently
280 protein and peptide-based
therapeutics molecules (excluding
antibodies) marketed for the
treatment of a variety of diseases,
ranging from cancer to HIV and
hepatitis. This group of products is
approved for the treatment of 283
indications across 22 therapeutic
areas. The report says there may
be a boom in coming years, as GBI
Research has identi ed 571 molecules
in the discovery, preclinical and
clinical stages of development.
These recorded compounds exist in
953 indication-speci c developmental
programs, and 629 programs are
currently in clinical development.
Indigenous mental health
beyondblue CEO Kate Carnell AO
commended research published in
the Medical Journal of Australia which
found that 73 per cent of Indigenous
men and 86 per cent of Indigenous
women in prison had a mental
disorder, compared with the 20 per
cent prevalence in the Australian
community. Ms Carnell agreed with
the authors' ndings that there is an
urgent need to develop and resource
culturally-relevant mental health
services for Indigenous Australians
in custody. 'We believe that an early
intervention approach is essential.
Many of the mental health issues
that lead to incarceration need to be
addressed during the formative years.
As a result, many of the programs
we are already funding for young
Indigenous people are designed
to build resilience and improve self
esteem,' she said.
Links Archive Australian Pharmacist September 2012 Australian Pharmacist July 2012 Navigation Previous Page Next Page